HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Autologous bone marrow transplantation in patients with acute nonlymphocytic leukemia, using ex vivo marrow treatment with 4-hydroperoxycyclophosphamide.

Abstract
We studied 25 patients with acute nonlymphocytic leukemia in second remission (20 patients) or third remission (5 patients) in whom autologous bone marrow transplantation was performed with use of marrow incubated ex vivo with the alkylating agent 4-hydroperoxycyclophosphamide. Patients received intensive cytoreductive therapy with busulfan and cyclophosphamide or cyclophosphamide and total body irradiation, followed by an infusion of marrow that had been collected in remission, treated with 4-hydroperoxycyclophosphamide, and cryopreserved. Four patients died from bacterial or fungal sepsis within the first month after transplantation, and one patient with persistent marrow hypoplasia died from gram-negative sepsis 155 days after infusion with autologous marrow. In the remaining patients, peripheral-blood levels of neutrophils in excess of 0.5 X 10(9) per liter and platelet counts over 50 X 10(9) per liter were attained at median intervals of 29 and 57 days after transplantation, respectively. Nine patients had leukemic relapses at 73 to 316 days (median, 182 days) after infusion of autologous marrow, for an actuarial relapse rate of 46 percent. Eleven patients (eight in second remission and three in third) remained in remission at a median of more than 400 days (range, greater than 230 to greater than 1653 days) after transplantation. The observed disease-free survival after transplantation with autologous marrow treated with 4-hydroperoxycyclophosphamide compares favorably with the results of syngeneic or allogeneic transplantation in similar groups of patients.
AuthorsA M Yeager, H Kaizer, G W Santos, R Saral, O M Colvin, R K Stuart, H G Braine, P J Burke, R F Ambinder, W H Burns
JournalThe New England journal of medicine (N Engl J Med) Vol. 315 Issue 3 Pg. 141-7 (Jul 17 1986) ISSN: 0028-4793 [Print] United States
PMID3523241 (Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • 4-hydroxycyclophosphamide
  • Cyclophosphamide
  • Busulfan
Topics
  • Acute Disease
  • Adolescent
  • Adult
  • Bone Marrow (drug effects)
  • Bone Marrow Transplantation
  • Busulfan (administration & dosage)
  • Child
  • Child, Preschool
  • Clinical Trials as Topic
  • Colony-Forming Units Assay
  • Combined Modality Therapy
  • Cyclophosphamide (administration & dosage, analogs & derivatives)
  • Drug Therapy, Combination
  • Female
  • Humans
  • Leukemia (therapy)
  • Leukocyte Count
  • Male
  • Middle Aged
  • Platelet Count
  • Time Factors
  • Transplantation, Autologous
  • Whole-Body Irradiation

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: